R.M.SINCERBEAUX Capital Management LLC held its position in shares of Merck & Co. (NYSE:MRK) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,796 shares of the company’s stock at the end of the second quarter. R.M.SINCERBEAUX Capital Management LLC’s holdings in Merck & Co. were worth $564,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in the company. Americafirst Capital Management LLC acquired a new position in Merck & Co. during the second quarter worth approximately $115,000. NewSquare Capital LLC increased its position in Merck & Co. by 14.2% in the second quarter. NewSquare Capital LLC now owns 2,104 shares of the company’s stock worth $121,000 after buying an additional 261 shares in the last quarter. First New York Securities LLC NY acquired a new position in Merck & Co. during the second quarter worth approximately $121,000. QCI Asset Management Inc. NY increased its position in Merck & Co. by 1.1% in the second quarter. QCI Asset Management Inc. NY now owns 2,382 shares of the company’s stock worth $137,000 after buying an additional 27 shares in the last quarter. Finally, Lowe fs LLC increased its position in Merck & Co. by 1.8% in the second quarter. Lowe fs LLC now owns 2,619 shares of the company’s stock worth $151,000 after buying an additional 46 shares in the last quarter. 72.93% of the stock is owned by hedge funds and other institutional investors.
Shares of Merck & Co. (NYSE:MRK) traded up 0.61% during trading on Wednesday, hitting $62.84. 3,256,225 shares of the stock were exchanged. Merck & Co. has a 52 week low of $47.97 and a 52 week high of $64.00. The firm has a market capitalization of $173.77 billion, a price-to-earnings ratio of 34.47 and a beta of 0.68. The stock’s 50 day moving average price is $62.71 and its 200 day moving average price is $58.27.
Merck & Co. (NYSE:MRK) last posted its earnings results on Friday, July 29th. The company reported $0.93 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.02. The business had revenue of $9.84 billion for the quarter, compared to analyst estimates of $9.79 billion. Merck & Co. had a net margin of 13.01% and a return on equity of 23.41%. Merck & Co.’s revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.86 EPS. On average, equities analysts predict that Merck & Co. will post $3.75 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 15th will be issued a $0.46 dividend. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date is Tuesday, September 13th. Merck & Co.’s payout ratio is 101.10%.
A number of equities analysts have recently commented on MRK shares. Vetr upgraded shares of Merck & Co. from a “sell” rating to a “buy” rating and set a $62.26 price objective for the company in a research note on Monday, July 4th. Argus restated a “buy” rating on shares of Merck & Co. in a research note on Thursday, June 9th. Jefferies Group increased their price objective on shares of Merck & Co. from $50.00 to $53.00 and gave the stock a “hold” rating in a research note on Thursday, July 14th. Leerink Swann reiterated a “hold” rating and issued a $58.00 target price on shares of Merck & Co. in a research note on Thursday, July 14th. Finally, Credit Suisse Group AG reiterated a “hold” rating and issued a $59.00 target price on shares of Merck & Co. in a research note on Wednesday, July 13th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the company’s stock. Merck & Co. has a consensus rating of “Hold” and a consensus price target of €63.20 ($70.23).
In other news, Chairman Kenneth C. Frazier sold 392,000 shares of the company’s stock in a transaction on Friday, August 5th. The shares were sold at an average price of €61.81 ($68.68), for a total value of €24,229,520.00 ($26,921,688.89). Following the completion of the sale, the chairman now owns 760,877 shares of the company’s stock, valued at approximately €47,029,807.37 ($52,255,341.52). The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Weir Mirian M. Graddick sold 40,800 shares of the company’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of €62.07 ($68.97), for a total transaction of €2,532,456.00 ($2,813,840.00). Following the completion of the sale, the insider now directly owns 128,973 shares of the company’s stock, valued at approximately €8,005,354.11 ($8,894,837.90). The disclosure for this sale can be found here. 0.05% of the stock is currently owned by insiders.
About Merck & Co.
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.